We tested the same panel of EBV-positive NPC cell lines (29, 30) for sensitivity to noncanonical pathway inhibition using a small molecule inhibitor, B022, which inhibits NIK (NF-κB–inducing kinase)–induced p100 – p52 processing (51). The gene discussed is NFKB2; the disease is nasopharyngeal carcinoma.